Tempest Therapeutics (TPST)
(Real Time Quote from BATS)
$3.56 USD
+0.02 (0.57%)
Updated Apr 29, 2024 02:35 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Income Statements
Fiscal Year end for Tempest Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 29 | 35 | 27 | 36 | 45 |
Income After Depreciation & Amortization | -29 | -35 | -27 | -36 | -45 |
Non-Operating Income | 1 | 1 | 0 | 0 | 0 |
Interest Expense | 1 | 2 | 1 | 0 | -1 |
Pretax Income | -29 | -36 | -28 | -36 | -45 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -29 | -36 | -28 | -36 | -45 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -29 | -36 | -28 | -36 | -45 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -29 | -34 | -27 | -35 | -44 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 0 | 1 | 1 |
Income After Depreciation & Amortization | -29 | -35 | -27 | -36 | -45 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 15.44 | 11.56 | 3.79 | NA | 0.91 |
Diluted EPS Before Non-Recurring Items | -1.91 | -3.09 | -7.47 | NA | -48.73 |
Diluted Net EPS (GAAP) | -1.91 | -3.09 | -7.47 | -28.94 | -48.73 |
Fiscal Year end for Tempest Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 7.51 | 6.59 | 7.47 | 7.58 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -7.51 | -6.59 | -7.47 | -7.58 |
Non-Operating Income | NA | 0.40 | 0.18 | 0.24 | 0.29 |
Interest Expense | NA | 0.38 | 0.37 | 0.36 | 0.34 |
Pretax Income | NA | -7.49 | -6.79 | -7.58 | -7.64 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -7.49 | -6.79 | -7.58 | -7.64 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -7.49 | -6.79 | -7.58 | -7.64 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 15.44 | 14.14 | 14.04 | 13.88 |
Diluted EPS Before Non-Recurring Items | NA | -0.34 | -0.48 | -0.54 | -0.55 |
Diluted Net EPS (GAAP) | NA | -0.34 | -0.48 | -0.54 | -0.55 |